Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The aim of this present study is to collect additional data for the post-marketing follow-up of Biodentine™ XP and measure long-term (up to 10 years) performance and safety of the biomaterial in all its indications.
Full description
This clinical investigation is done according to the European Medical Device Regulation (MDR) 2017/745 and is considered as an observational, post-market clinical follow-up study with no additional invasive and cumbersome procedures. Biodentine™ XP has been marketed in the US since 2022 and was launched in Europe in May 2023.
The aim of the study is to collect additional data for the post-marketing follow-up of Biodentine™ XP and measure long-term (up to 10 years) performance and safety of the biomaterial in its coronal restorative and endodontic dental indications.
The investigators participating in the clinical investigation will be general dental surgeron practitioners, with a great experience in restorative and endodontic indications or in pediatric dentistry, also users of Biodentine™.
This Clinical Investigation is an Observational, Prospective, and Multicenter study. This clinical investigation will take place in several investigational centres in France and Belgium.
This Clinical InvestigatioI is a prospective study: Patients will be treated with the study device (according to its CE-marked Instruction For Use), then followed up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patient with one or more documented contraindication to use Biodentine™ XP (Refer to IFU).
Inadequate expected tooth lifetime as estimated by the investigator:
Patient with any systemic disease that may hinder the normal healing process and/or the follow-up.
Adult patient under legal protection measures or unable to express his/her consent, and individual deprived of liberty by judicial or administrative decision, as well as individual receiving psychiatric care.
Periodontitis (stage 3, 4 or stage 2 grade C).
Inability to comply with study procedures.
Participation in another interventional clinical investigation that can induce bias in the study results.
275 participants in 3 patient groups
Loading...
Central trial contact
Farid BENABDALLAH, .MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal